AMGN · 8-K · 20260804PR000124

Competition and Pricing Pressure

AMGEN INC · 2026-08-04 · Importance 59 · Surprise 48 · No source text

Multiple global biosimilars pressured denosumab products, with Prolia volume down 20% and net selling price down 12%, while XGEVA volume fell 22% and net selling price fell 8%. Enbrel net selling price declined 22%, reflecting U.S. Medicare Part D price setting under the Inflation Reduction Act and increased 340B Program mix. Otezla sales declined on 9% lower net selling price and 6% lower volume, while MVASI sales fell 20% on 16% lower net selling price and lower volume. PAVBLU sales rose 121% to $287 million, supported by its position as the only commercially available biosimilar to EYLEA in the U.S. during the period.

Key facts

• Prolia sales decreased 32% year-over-year to $759 million in the second quarter, driven by 20% lower volume and 12% lower net selling price as multiple biosimilars have launched globally with more biosimilars expected. source
• Enbrel sales decreased 4% year-over-year to $580 million in the second quarter, primarily driven by 22% lower net selling price, partially offset by 16% favorable changes to estimated sales deductions. source

Impact estimates